personnel interested in supporting catheter laboratory procedures and close cooperation with the United Kingdom's regulatory authority (the Medicines and Healthcare Products Regulatory Agency), as well as with the centre's research and development and ethics staffs. Essential input also came from the company providing the valve, CoreValve, of Irvine, Calif. Dr Kovac says, "The most important aspect of all this was perseverance and patience, as well as getting a multidisciplinary team together." Glenfield Hospital is run by the University Hospitals of Leicester National Health Service Trust, and persuading the authorities to go in this innovative direction was helped by the good results achieved with other structural heart interventions. Dr Kovac adds, "The authorities realised that this procedure would really put the trust and the unit at the forefront of interventional cardiology nationwide and internationally."
Funding for the introduction of percutaneous aortic valve replacement at Glenfield has been shared between the trust's research funding, National Health Service money for patients with this type of aortic valve disease, and CoreValve. Dr Kovac says, "There was no need to invest in new equipment, as the device is provided for us, and our cath laboratory has got all the contemporary equipment and imaging equipment for all possible cardiac interventions. The PAVR procedure uses standard fluoroscopy and image acquisition." He explains, "We have 6 spacious, good-quality cath labs, which give us excellent temporal and geographical space for innovative procedures. A decent-sized catheter laboratory is an advantage for this programme."
Dr Kovac has been an interventional cardiologist for over 15 years and performed over 5000 coronary angioplasties, but he also routinely performs noncoronary interventions, carrying out a large number of mitral and aortic valvuloplasties, as well as septal closure procedures. He says, "Glenfield became involved in the PAVR project from the beginning, but due to differences in regulatory processes among countries, participation started later with us than it did for doctors in Germany and some other mainland Europe countries." Worldwide, participating countries include Belgium, the Netherlands, and Canada, as well as Venezuela and India, which began their involvement in the form of First in Man studies.
Dr Kovac points out, "The technology for this particular PAVR procedure is neither commercially nor investigationally available in the United States." He adds that Glenfield is very grateful to Eberhard Grube, MD, of the department of cardiology and angiology at the Siegburg Heart Centre, Germany, and Gerhard Schuler, MD, of the department of internal medicine and cardiology at the University of Leipzig Heart Centre, Germany, for providing insights and sharing experiences that were pivotal to the success of their first procedures.
Dr Kovac is enthusiastic about the advantages of PAVR ( Figure 2 ), particularly its potential to shorten the hospital stay for patients, and the cost reductions it makes possible in terms of time in theatre and in intensive care compared with open-heart surgery. He says, "Our first cohort of patients went home in 48 hours and are doing fine. The patients are symptom free, the valves are functioning well, and despite their advanced age, the patients have resumed the active life they have not had for some time." He notes that the rapid return to a higher quality of life was remarkable. "Reduction of time spent in hospital seems to be significant. With conventional surgery, it is about 10 days, which includes a stay on the intensive care unit for 1 or 2 days. The savings to healthcare systems come about because there is no need for full cardiac anaesthesia, no cost of perfusion, and much less posthospital rehabilitation."
More procedures are planned, alternating with other European centres involved in a pivotal study of the procedure. Dr Kovac stresses, "This is a very exciting field, but it is very important that it is taken on after proper preparation of the whole team. It is not just another coronary angioplasty." He says the procedure requires additional imaging and practical skills from interventionists and supporting catheter laboratory staff, such as the ability to work in different projections, and to become accustomed to different tactile feelings when handling the device, expertise in balloon aortic valvuloplasty, and familiarity with novel closing devices. Also essential is the ability to direct procedure and feedback from fluoroscopy, as well as transoesophageal echocardiography and intracardiac echocardiography. Dr Kovac emphasises, "Multidisciplinary collaboration in selection and treatment of patients is necessary."
There has been immense interest in the procedure from across the United Kingdom and globally, and Dr Kovac believes it has implications for the way physicians will treat aortic valve disease in the future. "My experience from these procedures as an interventional cardiologist is to think more as a surgeon in terms of valve sizing and positioning, as well as aftercare." He now believes surgeons will look at different parts of the anatomy for access sites and explore techniques of closing larger access sites with novel closure devices. "We expect to be joined in our study by 1 or 2 other UK centres very soon, and we will be involved in training them," he says. "This field will develop over the next few years, but for the immediate future it will be probably limited to a few cardiac centres in each country. But over the years, I foresee its adaptation as a procedure spreading to most cardiac centres."
At the moment, Glenfield hospital carries out approximately 200 aortic valve cardiac surgical procedures out of around 200 000 conducted annually worldwide by about 5000 surgeons. It is known that in different centres approximately one third of patients with aortic valve disease are not operated on because of comorbidities. Dr Kovac observes, "The prognosis of these 'inoperable' patients is very poor, with short-term yearly mortality of 25% plus. On top of that, 30% of patients receiving surgery are considered high risk, so the immediate patient population for PAVR is a combination of those 2." He concludes, "In our capacity as a national referral centre, I can foresee us handling hundreds of PAVR procedures without a change in the number of heart operations offered to normal-risk patients. Beyond that depends very much on the further development of technology, with the real possibility of ultimately replacing conventional open-heart valve surgery with some variations of pure percutaneous access and transapical keyhole access." f81 Circulation
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I n 1944 whilst World War II still raged, a small group of prominent Spanish physicians founded the Spanish Society of Cardiology. Their president was Carlos Jimenez Diaz, MD, a professor and distinguished internist with a modern concept of medicine. But these were hard times for science and medicine in Spain, where one result of the Civil War that ended in 1939 was to drive many researchers abroad. The country was following its own political path under El Caudillo General Francisco Franco, and lack of investment in research and health care prevented Spain from sharing in the enormous advances in cardiology being made elsewhere. Dr Francisco Cosio, chief of the cardiology service at the University Hospital of Getafe, Madrid, says, "It was not until the early 1970s that the speciality started to fall into line with the rest of Europe. Before then, there were no national training schemes, few modern hospitals, and the facilities were generally poor."
Although Dr Cosio's home town of Oviedo, where his father was a prominent chest physician, had a modern hospital, he decided as a young man to further his medical education in the United States, where he spent 6 years at the University of Minnesota Hospitals, Minneapolis. He obtained a residency in internal medicine at Hennepin County General Hospital, Minneapolis, Minn, and then undertook 2 years' cardiology training. He recalls, "Electrocardiography, phonocardiography, pulse recording, and catheterisation were the tools available. Coronary angiography was the great new advance, and bypass surgery was almost at its beginning. Electrophysiology was taking its initial steps and echocardiography was a new interesting technique in which a single ultrasound beam probed the heart and you identified the structures by their motion on the line defined by the beam."
When Dr Cosio returned to Spain in 1973, things had started to change. "The early 1970s saw the birth of modern hospital medicine in this country," he says. "Social security was well funded and large investments took place, with new hospitals being built throughout the country. This coincided with the return to Spain of large numbers of doctors who had, like me, been trained elsewhere." But unlike in some other countries, Spanish cardiology did not obtain its impetus from the universities but tended to develop in the new public hospitals that worked outside the university setting. Dr Cosio observes, "At the time, university hospitals were set in their ways. They depended more on authority than science. There was more freedom to develop outside. There is still a trace of this in the older university hospitals, where power struggles can still occur."
Students at Spain's 40 medical schools spend 6 years studying for the licenciado. Until recently, the number of those who could qualify was unlimited, but despite its name the licenciado gives no licence to practise. To qualify
Climbing the cardiology career ladder: Spain In Spain, Women Residents Outnumber Men, Seniority Counts More Than Publications, and Every Step Is Contested
Determination is no stranger to those pursuing a career in cardiology, but to be successful job applicants in Spain must be particularly determined, with training positions subject to open auction and with those who are chosen enduring appeals from other candidates before being able to take up their posts. Francisco G Cosio, MD, FESC, chief of the cardiology service at the University Hospital of Getafe, Madrid, explains the process to Barry Shurlock MA, PhD.
for a training place in family medicine or one of the specialities, budding doctors must pass a highly competitive examination, the examen MIR, which involves multiple-choice questions and lasts up to 5 hours, all in a single day. Most candidates are likely to spend a minimum of 9 months after the licenciado studying at one of the private schools that specialise in coaching pupils specifically to take this exam.
About 6000 training positions are offered each year, competed for by about three times as many candidates. The ranking of each candidate depends largely on the score obtained in the examen MIR, but account is also taken of the grade awarded at medical school. Once candidates have been ranked, an open auction for training positions takes place, with the highestranked candidate having the first choice. Cardiology positions are quickly taken and are usually all filled by the time the thousandth candidate out of the 6000 has chosen. Those candidates who desperately seek a cardiology residency but fail to obtain one may settle for, perhaps, a residency in family practice or internal medicine but take the examen MIR again in the meantime, sometimes several times, to try and achieve their goal.
The fortunate few who are accepted as cardiology residents-currently about 120 a year-spend 5 years at one or more of the public or private hospitals that are certified for training. The course follows a conventional pattern, with the first year spent in general medical training, rotating through the specialities. Subsequent years are spent on the wards and in the critical care unit, as the doctor progresses to noninvasive and then invasive procedures. The training ends with short rotations in cardiac surgery and paediatric cardiology.
Dr Cosio takes 2 new residents each year. He explains, "Assessments of a resident's progress are relatively informal. Records are kept of the procedures carried out, and each resident is evaluated each year by local tutors and the teaching commission of the hospital (Comisión de Docencia)." He continues, "No real effort is made at classifying them, and it is very rare that a cardiologist does not finish the training. There may be the occasional disenchantment along the way, but most obtain their certificado de residencia, which entitles them to receive the título de cardiólogo, or cardiologist's diploma. This is awarded by the Ministry of Education and Science." Interventional cardiology and electrophysiology are recognised subspecialities that require an additional 1 to 2 years' training, generally in the same hospital.
An unusual feature of Spanish cardiology, and medicine in Spain in general, is that it is currently recruiting about twice as many women as men. The present membership of the Spanish Society of Cardiology is still predominantly male, but the situation is rapidly shifting. This situation contrasts with that of most other European countries, where women view cardiology as too "macho" and believe that the demands of the job impinge too greatly on family life. Dr Cosio comments, "There are more women than men coming into cardiology here, including one of my daughters! The practice of cardiology, and medicine in general, is going to change. Women are so very practical and are beginning to say, 'I have my hours for work and I have my family, and the 2 are separate.' Hence, we probably will need more cardiologists."
Two years ago, in May 2005, Dr Cosio received the Distinguished Teacher Award of the Heart Rhythm Association at its annual congress, held in New Orleans, La, 4 months before the tragedy of Hurricane Katrina. This award was in recognition of his pioneering work carried out at the University Hospital of Gatafe on the mechanism and treatment of atrial flutter by catheter ablation techniques (see Figure) . Innovation at this level is, however, relatively rare in Spain, where most hospitals are not linked to universities and original research is not a high priority.
Dr Cosio says, "People are not so crazy about research as they used to be. Hospital politics are driven by trade unions, and seniority is more important than a list of publications. However, the younger man with a list of publications might have a better chance of obtaining a job in a large university hospital if the chief of that service builds the necessary creative tension by making more senior cardiologists take jobs in smaller city hospitals, which are perceived to offer a better quality of life."
The process of obtaining a permanent post in a Spanish hospital involves an open contest, or oposición, lasting a whole day, during which all candidates make presentations and argue their case for appointment. Another day is then taken by the selection committee to mark the candidates' curriculum vitae according to a set of rules that account for about 60% of each candidate's final score. The balance of 40% of the marks is based on examinations taken by candidates and on general assessments of the committee. "It is a process in which the chief of service can only expect to appoint the candidate of his choice in about two-thirds of cases," says Dr Cosio. "And everything is not over, even when the chosen job applicant is announced, since other candidates have the right to lodge an appeal against the commission's decision." He concludes, "It's a very complex procedure. There are all sorts of reasons for appealing. It may take months to settle in some cases. Seniority is very important, and for that reason not many Spanish cardiologists train abroad. They are afraid of not having a job when they get back. It may change in the near future, as large numbers of those who began their careers in the early 1970s will be retiring: about 20% to 30% over the next 5 years." f83 Circulation
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R eferring to the career path that led research diabetologist Dr Carolyn Deacon from her laboratory studies to addressing clinical cardiologists, she says, "It was chance in a way." Dr Deacon's contribution to the development of therapeutic agents that tackle the glucose-control aspects of diabetes and reduce the long-term risk of cardiovascular complications of the disease means that she is now sharing her knowledge with much wider audiences.
Most of her current work stems from her decision in the mid-1990s to move to Denmark when her husband was offered a job in the pharmaceutical industry in Copenhagen. Before making that move, she had gained a PhD in zoology from Sheffield University, where she later returned for a second postdoctoral post; she also had done a 3-year stint in Germany at the Max Planck Institute, Göttingen. It was during this placement that Dr Deacon learned the basic techniques that have underpinned her career. She explains, "In Germany, I was developing new techniques for identifying and measuring hormones and their metabolites. I learnt techniques that I am using today, and once you have them you can apply them to different fields."
Her experience in Germany also yielded several contacts, which made the transition to Denmark relatively easy. Once in Denmark, she started looking at hormones as therapeutic agents, particularly the incretin peptide glucagon-like peptide-1 (GLP-1), examining how they were metabolised and whether the metabolites of these compounds were active in the body.
After 14 years in Denmark, and currently a senior lecturer at the Panum Institute at the University of Copenhagen (see Figure) , Dr Deacon is now a confident Danish speaker and lectures and teaches in the language. "But it didn't start out like that," Dr Deacon recalls. "Without any knowledge of the language, I and my husband had lessons in Danish twice a week for 6 months." This was at the beginning of their residence in the country. "But," she explains, "a lot of our language learning was picking it up as we went along." In particular, their colleagues were very supportive.
Viewpoint: Carolyn Deacon, PhD, DMSc
Dr Carolyn Deacon's career has led her from laboratory studies of the pathophysiology of diabetes mellitus to lecturing cardiologists at European conferences. She gives her views on her chosen specialisation and explains to Hannah Brown, BSc, how she attributes this path largely to chance.
The Panum Institute, University of Copenhagen, where Dr Deacon started looking at hormones as therapeutic agents, particularly the incretin peptide GCP-1.
The Panum Institute "People would help in the lab by asking me questions in Danish, and I would answer in English. As I got better, I would start to respond in Danish." The medical students were a help, too. "All their lecture notes and textbooks are in English, so they have a reasonable grasp of the language. They would ask questions in Danish and I would reply in English to begin with, but it gradually switched over. I have been teaching in Danish since 2000."
Dr Deacon says she has always had an interest in endocrinology, but the link with cardiology only emerged because of the discovery of the cardiac effects of GLP-1. From these beginnings as very basic science, Dr Deacon's work is now bringing her into contact with clinical cardiologists, as the drugs she started working on are now used in patients. "There is a big debate between the cardiologists and diabetologists about whether diabetes is a metabolic or cardiovascular disease," she says. "It is now clear that glucose control in patients with diabetes is not enough to stave off the macrovascular effects of the disease, and so there is increasing interaction between the 2 disciplines because we don't know where the big problems are."
Dr Deacon thinks the increasing interest of cardiologists in work like hers-on the pathophysiology of the hormonal aspects of diabetes-is attributable to a "developing awareness and interest in understanding the new developments in the pathogenesis of the disease and how hormones affect that." And it looks as if the disciplines may come even closer together because of the necessity of finding new ways of controlling diabetes that also lower long-term risk of cardiovascular problems. Dr Deacon explains, "If you end up with a treatment that you are using to control glucose levels and it also has an effect on cardiovascular outcomes, then that would be better than current treatments because none of them can do that."
Since moving to Denmark, Dr Deacon has been following up on a hypothesis she first published with Danish colleagues in 1995: that inhibiting the degradation of GLP-1, which also has receptors on pancreatic and heart cells, may be an effective treatment for diabetes. Two classes of compound based on the actions of GLP-1, the dipeptidyl peptidase-4 inhibitors and stable GLP-1 analogues, are now on the market and being used to treat patients, a milestone that Dr Deacon says has given her a satisfaction that laboratory scientists don't often experience. "You start off doing scientific research and hope that something will contribute to healthy lifestyles," she says, "so this is very rewarding." She believes that the incretin hormones have therapeutic potential beyond just stimulating secretion of insulin. Making compounds that are based on the actions of GLP-1 part of an effective therapeutic strategy involves learning more about the actions of GLP-1, how it is broken down by the body, and what happens to the metabolites. But Dr Deacon says that the long-term effects with potential cardiovascular benefits are the really interesting area of research at the moment. The scientific rationale is that, just like pancreatic islet cells, heart cells also express receptors for GLP-1, which is secreted after meals and regulates a number of processes involved in blood glucose control.
"If you look at mice with a knockout of the GLP-1 receptor, they have disturbed cardiac function," explains Dr Deacon. "That prompted people to start looking at perfused hearts with experimentally induced infarcts in vitro to see if GLP-1 could make those infarcts less severe." Now that hundreds of patients have been treated for diabetes with incretin-based drugs, she says that much interest exists in seeing whether the cardioprotective effects observed in animal models are repeated in humans.
"There is a great deal of interest looking at the long term. The hypothesis is only really supported with animal data at the moment. We are trying to keep up to date on cardiovascular effects to keep an eye on any developments," Dr Deacon says.
Cardiovascular problems in patients with diabetes mellitus are currently an area of unmet need. "So the incretinbased therapies, including dipeptidyl peptidase-4 inhibitors, have the potential to substantially improve care for patients," says Dr Deacon. "We don't see the cardioprotective effect with other agents, which only target 1 or 2 of the underlying defects in diabetes. However, the incretinbased approach is targeting on many different levels." She continues, "They also lower body weight by lowering appetite. Most treatments cause patients to gain weight and thereby worsen cardiovascular outcomes." Future trends seem likely to bring diabetologists and cardiologists even closer together. Dr Deacon predicts, "Given that the cardiac problems of diabetes are the biggest cause of mortality, there is going to be increasing interest on both sides."
